Short answer
Nuvectis Pharma, Inc. (NVCT) filed an 8-K current report with the SEC on June 23, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Exclusive ex-China rights for NXP100 Factor B inhibitor and NXP200 BRAF inhibitor, expanding Nuvectis’s development pipeline.
Nuvectis Pharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Exclusive ex-China rights for NXP100 Factor B inhibitor and NXP200 BRAF inhibitor, expanding Nuvectis’s development pipeline
- $20 million upfront payment plus up to $20 million in early development milestones
- Up to $1.4 billion in contingent development, regulatory and commercial payments
- Tiered royalties from high-single digits to mid-teens on Territory net sales
- Agreement depends on financing conditions, creating near-term capital requirements before effectiveness
Item 8.01 · Other Events
- Nuvectis announced entry into a License Agreement on June 22, 2026
- Press release filed as Exhibit 99.1 contains the substantive agreement details
- Licensing announcement may affect product rights, development strategy, and future commercialization prospects
Item EX-99.1 · Exhibit EX-99.1
- Exclusive ex-China rights add late-stage NXP100 and Phase 1b NXP200, transforming Nuvectis into a broader clinical development company
- NXP100 PNH response 59.5% versus 8.3% for eculizumab, with two Chinese marketing applications under review
- NXP100 targets complement diseases including PNH, IgAN and lupus nephritis, expanding beyond Nuvectis’ oncology focus
- Haisco eligible for up to $40M upfront and near-term payments plus $1.421B in milestones and tiered royalties
- Financing conditions require Nuvectis to secure sufficient capital, creating potential funding and dilution risk for development programs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nuvectis Pharma, Inc. 8-K filings
Get the next NVCT 8-K as it lands
Follow NVCT for push alerts, or ask the research agent what this filing means.